Swiftset for Contact Dermatitis

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Memorial Hermann, Houston, TXContact Dermatitis2-Octylcyanoacrylate (Dermabond) - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing two different ways to close surgical ports. One is 2-Octylcyanoacrylate and the other is n-butyl-2-cyanoacrylate.

Eligible Conditions
  • Contact Dermatitis

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: 6 weeks

6 weeks
contact dermatitis
diameter of erythema
mean diameter of erythema
proportion of patients who develop contact dermatitis
proportion of patients with surgical site infection
proportion of patients with wound dehiscence
surgical site infection
wound dehiscence

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Swiftset
1 of 2
Dermabond
1 of 2

Active Control

186 Total Participants · 2 Treatment Groups

Primary Treatment: Swiftset · No Placebo Group · Phase 3

SwiftsetActiveComparator Group · 3 Interventions: 2-Octylcyanoacrylate (Dermabond), 2-Octylcyanoacrylate, N-butyl-2-cyanoacrylate · Intervention Types: Device, Device, Device
DermabondActiveComparator Group · 3 Interventions: 2-Octylcyanoacrylate (Dermabond), 2-Octylcyanoacrylate, N-butyl-2-cyanoacrylate · Intervention Types: Device, Device, Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 weeks

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
817 Previous Clinical Trials
258,842 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Does Swiftset meet the criteria for safety and efficacy set by the FDA?

"There is some evidence from earlier phases that Swiftset is effective, as well as data from multiple rounds of testing that support its safety--our team rates it a 3." - Anonymous Online Contributor

Unverified Answer

Are we still able to enroll new participants for this clinical study?

"This medical trial is currently looking for patients to enroll. According to the information on clinicaltrials.gov, the trial was originally posted on June 29th, 2022 and was last updated on August 11th, 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.